APA (7th ed.) Citation

EY, Y., H, L., CS, H., N, A., SK, P., A, A., . . . Jr, T. I. (2015). SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(14), 1601. https://doi.org/10.1200/JCO.2014.59.4127

Chicago Style (17th ed.) Citation

EY, Yu, et al. "SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 33, no. 14 (2015): 1601. https://doi.org/10.1200/JCO.2014.59.4127.

MLA (9th ed.) Citation

EY, Yu, et al. "SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 33, no. 14, 2015, p. 1601, https://doi.org/10.1200/JCO.2014.59.4127.